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The terminology of first, second and third world dates from
the times of the cold war and refers to the United States of
America and its allies, the old communistic countries in-
cluding China, and the non-aligned countries (among them
Indonesia), respectively. As the world moves on in the 21st
century, rapid changes in this concept can be observed. In
the current issue of our journal the title of the article by
Dharma et al., is somewhat misleading as “the third world”
as we knew it does not exist anymore [1]. They describe
their experience with treatment of ST-elevation myocardial
infarction (STEMI) in the city of Jakarta, Indonesia.
The Indonesian health care providers represent a mix of
public and private institutions, roughly half of them owned
by private investors [2]. Experience, logistics and patient
characteristics may differ profoundly in different parts of
Indonesia, but it was demonstrated that primary percutane-
ous coronary intervention (pPCI) for STEMI can obtain
good results with regard to restoration of TIMI-3 flow in
the infarct-related vessel, in a “third world” setting [2, 3].
However, time delays between symptom onset as well as
between admission and first balloon inflation are consider-
ably longer [3]. The main problem with pPCI is that it is not
readily available to most patients with STEMI. Many
STEMI patients still receive thrombolytic therapy or no
reperfusion at all, owing to the limited availability of pPCI
and other resources. Besides, many community hospitals do
not have the annual PCI volume needed to maintain the
skills of the interventionalist and the cardiac catheteriza-
tion laboratory staff, which is crucial in the treatment of
STEMI patients (especially when they are at high-risk or
hemodynamically unstable.) As the authors correctly state,
the percentage of STEMI patients not receiving reperfusion
therapy is too high - almost 60 % - and this number needs to
be reduced bij programmes [4]. Furthermore, of the two
reperfusion options, pPCI is by far the best treatment and
should be available for all who need it, whether it is in the
“first” or in the “third world”. For advanced medical care,
Indonesia relied and was dependent untill very recently, on
hospitals in other countries like Singapore. They provided
heart surgery and coronary interventions for many people
from Indonesia over the years, but in the case of STEMI
patients there is no time for transportation and any delay
is deleterious, creating the need for well equipped car-
diac intervention centers in Indonesia, like the National
Cardiovascular Center “Harapan Kita” in Jakarta.
But many questions remain: What about the use of ad-
junctive but expensive therapy, like glycoprotein 2b/3a
blockers, new drug eluting stents and intra-aortic balloon
pumping in a “third world” setting? Many patients will need
implantable defibrillator and/or resynchronization treatment
as well, after surviving a STEMI. Dharma and co-workers
do not give information on this but fibrinolytic therapy
remains one of the cornerstones of therapy in Indonesia,
especially in isolated and rural areas, but also cities like
Jakarta. The city of Jakarta itself - some 10 million people,
and by far the largest city in South-East Asia - is suffering
from a large traffic and transportation infarct and timely
arrival in a hospital with interventional cardiology facilities
(which is crucial for a good clinical outcome) may simply be
impossible.
But the main problem remains unaddressed: how to pro-
vide general access to optimal medical care for STEMI in
“third world” countries? (By the way, what about the 50
million of uninsured citizens in the U.S.A. - supposed to be
part of the “first world” - where paradoxically the highest
costs of medical care per person are reported [5].)
M. J. de Boer (*):H. Suryapranata
University Medical Center St Radboud,
Geert Grooteplein 10,
6525 GA Nijmegen, the Netherlands
e-mail: ereis@planet.nl
Neth Heart J (2012) 20:252–253
DOI 10.1007/s12471-012-0291-9And how about pPCI facilities in Europe (the “old con-
tinent” or “first world”)? Although pPCI has been widely
implemented, there are still major differences in PCI facili-
ties and reperfusion strategy among European countries. In
fact, too many STEMI patients still do not receive any
reperfusion therapy in some European countries (Fig. 1).
But more importantly, many European countries have made
tremendous progress in pPCI. In fact, implementation of a
pPCI strategy, relying on better logistics and hospital infra-
structure has increased the overall use of reperfusion thera-
py, resulting in a significant decrease in cardiovascular
mortality. However, it took more than 15-years since the
first publications in 1993 to achieve this stage. Therefore,
nationwide implementation of pPCI remains to be devel-
oped, not only in the “third world”, but also in many
European countries. It was recently estimated that world-
wide, more than 10.000 hospitals provide invasive reperfu-
sion therapy in patients with STEMI nowadays. Still there is
a continuing controversy about the acceptable time-window
for pPCI. The evidence supports an acceptable pPCI-related
delay of 80–120 min [6], and the median door to treatment
time of 38 and 95 min for “needle” and “balloon” respec-
tively, reported from Jakarta “Harapan Kita” National Hos-
pital stands well against other countries.
Indonesia seems to be on the right path: large companies
and the government already installed health care systems for
open access and the formerly “elitary treatment” only for
those who are very rich or well to do is abandonned but not
yet history. Dharma and colleagues are to be congratulated
on this first step by sharing their data with us.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Dharma S, et al. Acute myocardial infarction system of care in the
third world. Neth. Heart J. 2012. doi:10.1007/s12471-012-0259-9.
2. Juwana YB. Optimizing primary PCI for ST-elevation myocardial
infarction. Thesis Radboud University Nijmegen; 2011.
3. Juwana YB, Wirianta J, Ottervanger JP, et al. Primary coronary
intervention for ST-elevation myocardial infarction in Indonesia
and the Netherlands: a comparison. Neth Heart J. 2009;17:418–21.
4. Keeley EC, Grines CL. Controversies in cardiovascular medicine.
The case for emergency transfer for primary percutaneous coronary
intervention. Circulation. 2005;112:3509–34.
5. Source: NRC-Handelsblad, march 19, 2012
6. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to
treatment and mortality in primary angioplasty for acute myocardial
infarction: every minute of delay counts. Circulation. 2004;109:1223–5.
Fig. 1 STEMI treatment in European hospitals in 2010 (data from
national registries or surveys). 100 % of all hospitalized STEMI
patients in each given country; light grey, STEMI patients treated by
primary PCI; dark grey: STEMI patients treated by thrombolysis;
black, STEMI patients not treated with any reperfusion. Countries: 1:
the Netherlands; 2: Czech Republic; 3: Slovenia; 4: Norway; 5:
Denmark, 6: Belgium; 7: Poland; 8: Switzerland; 9: Croatia; 10:
Sweden; 11: Hungary; 12: Germany; 13: Israel; 14: Finland; 15: Italy;
16: Spain; 17: Slovakia; 18: Austria; 19: Portugal; 20: Serbia; 21:
Bulgaria; 22: Greece; 23: Turkey; 24: Romania; 25: Russia. (Provided
very kindly by professor Petr Widimsky)
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